Dickinson R, Presgrave P, Levi J, Milliken S, Woods R
Department of Clinical Oncology, Royal North Shore Hospital, St. Leonards, NSW, Australia.
Cancer Chemother Pharmacol. 1989;24(1):67-8. doi: 10.1007/BF00254110.
A total of 23 patients with advanced gastric adenocarcinoma were treated with a combination of moderate-dose methotrexate (MDMTX), 250 mg/m2 i.v., with folinic acid rescue and 5-fluorouracil (5-FU) 600 mg/m2 i.v. Therapy was given every 7 days for 4 courses and then at 14-day intervals. All patients were evaluable for response. No complete responses occurred, but five patients (22%) had partial remissions (95% confidence limit, 5%-39%). The median duration of remission was 6 months, with a median survival of 11 months amongst responding patients. In all, six patients (26%) had stable disease for a median period of 5 months. The overall median survival was 6 months. Therapy was generally well tolerated, with principal toxicities consisting of neutropenia, nausea and vomiting, mucositis and diarrhoea. In terms of activity or survival in advanced gastric carcinoma, the combination of moderate-dose MTX and 5-FU does not appear to offer an advantage over single-agent therapy.
共有23例晚期胃腺癌患者接受了中剂量甲氨蝶呤（MDMTX）（静脉注射250 mg/m²）联合亚叶酸解救及5-氟尿嘧啶（5-FU）（静脉注射600 mg/m²）的治疗。每7天进行1个疗程治疗，共4个疗程，之后每14天进行1次治疗。所有患者均对疗效可进行评估。未出现完全缓解，但有5例患者（22%）出现部分缓解（95%置信区间为5%-39%）。缓解持续时间的中位数为6个月，缓解患者的中位生存期为11个月。共有6例患者（26%）病情稳定，中位稳定期为5个月。总体中位生存期为6个月。该治疗一般耐受性良好，主要毒性包括中性粒细胞减少、恶心呕吐、黏膜炎和腹泻。就晚期胃癌的活性或生存期而言，中剂量甲氨蝶呤与5-氟尿嘧啶联合治疗似乎并不比单药治疗更具优势。
